首页 | 本学科首页   官方微博 | 高级检索  
     

头孢呋辛联合盐酸氨溴索+莫西沙星治疗慢性支气管炎急性发作对患者体液免疫水平的影响
引用本文:宾诚玲,陈秀英,谢秀芳. 头孢呋辛联合盐酸氨溴索+莫西沙星治疗慢性支气管炎急性发作对患者体液免疫水平的影响[J]. 罕少疾病杂志, 2020, 27(4): 34-36. DOI: 10.3969/j.issn.1009-3257.2020.04.013
作者姓名:宾诚玲  陈秀英  谢秀芳
作者单位:四川省内江市第一人民医院呼吸与危重症医学科 四川内江 641000;四川省内江市第一人民医院呼吸与危重症医学科 四川内江 641000;四川省内江市第一人民医院呼吸与危重症医学科 四川内江 641000
摘    要:目的探讨头孢呋辛联合盐酸氨溴索与莫西沙星治疗慢性支气管炎急性发作对患者体液免疫水平的影响。方法选择150例慢性支气管炎急性发作患者为研究对象,按照随机数表法分为研究组与对照组各75例。对照组采用头孢呋辛联合莫西沙星治疗,研究组在对照组基础上加用盐酸氨溴索治疗。比较治疗10d后,两组患者治疗效果评估差异;比较治疗前及治疗10d后,两组患者体液免疫[免疫球蛋白(Ig)G、IgA、IgM]水平变化;比较治疗10d内,两组患者药物不良反应发生情况差异。结果治疗10d后,研究组患者治疗总有效率明显高于对照组(P<0.05);治疗10d后,两组患者IgG、IgA、IgM水平均较治疗前显著升高(P<0.05),且研究组明显高于同一时间对照组(P<0.05);治疗10d内,两组患者腹泻、恶心呕吐、皮疹发生率比较无统计学意义(P>0.05)。结论头孢呋辛联合盐酸氨溴索与莫西沙星治疗慢性支气管炎急性发作患者,可提高治疗效果,改善体液免疫水平,保证用药安全性。

关 键 词:头孢呋辛  盐酸氨溴索  莫西沙星  慢性支气管炎  急性发作  体液免疫

Effects of Cefuroxime Combined with Ambroxol Hydrochloride+Moxifloxacin on Humoral Immunity Level in Patients with Acute Exacerbation of Chronic Bronchitis
BIN Cheng-ling,CHEN Xiu-ying,XIE Xiu-fang. Effects of Cefuroxime Combined with Ambroxol Hydrochloride+Moxifloxacin on Humoral Immunity Level in Patients with Acute Exacerbation of Chronic Bronchitis[J]. Journal of Rare and Uncommon Diseases, 2020, 27(4): 34-36. DOI: 10.3969/j.issn.1009-3257.2020.04.013
Authors:BIN Cheng-ling  CHEN Xiu-ying  XIE Xiu-fang
Affiliation:(Department of Respiratory and Critical Care Medicine,The First People’s Hospital of Neijiang,Neijiang 641000,Sichuan Province,China)
Abstract:Objective To investigate the effects of cefuroxime combined with ambroxol hydrochloride and moxifloxacin on humoral immunity level in patients with acute exacerbation of chronic bronchitis.Methods A total of 150 patients with acute exacerbation of chronic bronchitis were selected as the research subjects,and they were divided into study group and control group according to the random number table method,with 75 cases in each group.Control group was treated with cefuroxime combined with moxifloxacin while study group was additionally given ambroxol hydrochloride on the basis of control group.After 10d of treatment,the treatment effects were compared between the two groups.Before treatment and after 10d of treatment,the changes of humoral immunity[immunoglobulin(Ig)G,IgA,IgM]were compared between the two groups.The occurrence of adverse drug reactions were compared between the two groups within 10d of treatment.Results After 10d of treatment,the total effective rate of treatment in study group was significantly higher than that in control group(P<0.05).After 10d of treatment,the levels of IgG,IgA and IgM in the two groups were significantly increased compared with those before treatment(P<0.05),and the scores in study group were significantly higher than those in control group at the same time point(P<0.05).Within 10d of treatment,there were no statistically significant differences in the incidence rates of diarrhea,nausea and vomiting and rash between the two groups(P>0.05).Conclusion Cefuroxime combined with ambroxol hydrochloride and moxifloxacin for patients with acute exacerbation of chronic bronchitis can enhance the treatment effects,improve the humoral immunity level and ensure the safety of medication.
Keywords:Cefuroxime  Ambroxol Hydrochloride  Moxifloxacin  Chronic Bronchitis  Acute Exacerbation  Humoral Immunity
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号